ADVERTISEMENT
Monday, March 8, 2021
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

USAMRIID-Bavarian Nordic Smallpox Vaccine Phase 3 Study

by Global Biodefense Staff
February 19, 2018
USAMRIID U.S. Army Medical Research Institute of Infectious Diseases
Concept drawing of smallpox. Credit: Shutterstock
Concept drawing of vaccinia. Credit: Shutterstock

Bavarian Nordic announced on Feb. 6 the results of a successful Phase 3 clinical trial led by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) that demonstrated the safety and efficacy of the company’s investigational, non-replicating smallpox vaccine, IMVAMUNE®.

The product is being developed as an alternative to the current U.S. licensed replicating smallpox vaccine, ACAM2000®, which cannot be used by certain populations, including people with atopic dermatitis and HIV. It is already approved in Canada and the European Union.

USAMRIID study director Phillip R. Pittman, M.D., collaborated with the U.S. Defense Health Agency to enroll 440 subjects at a U.S. military post in South Korea. The randomized, open-label study had two co-primary endpoints. The first was to show that IMVAMUNE induced a non-inferior antibody response when compared with ACAM2000. In this study, the peak neutralizing antibodies induced by IMVAMUNE were shown to be twofold higher than those stimulated by ACAM2000, demonstrating a statistically superior immune response.

The second co-primary endpoint was to demonstrate an attenuation or prevention of a “take” in volunteers previously vaccinated with IMVAMUNE. Historically, a take is a measure of efficacy against smallpox in people vaccinated for the first time. It consisted of a pustule, scab and scar that developed on the skin following initial vaccination with replicating smallpox vaccines like ACAM2000. Following the second vaccination, those who had developed a protective immune response showed either a reduced take or none at all. This also was achieved in the USAMRIID-Bavarian Nordic study.

“If approved, this vaccine will have a direct impact on improving force health protection for U.S. Soldiers and other service members who are required to be immunized against smallpox,” said COL Gary Wheeler, commander of USAMRIID.

According to Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic, IMVAMUNE has been given to more than 7,800 subjects in 21 clinical studies, including this trial and one other Phase 3 study. He said the company plans to file a Biological License Application with the U.S. Food and Drug Administration later this year.

“This program has only been possible through the consistent and strong support of numerous U.S. Government agencies and demonstrates what can be achieved through a successful public-private partnership to protect the public from the deliberate release of the smallpox virus,” Chaplin added.

Funding for the study was provided by the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100200700034C. Study details are available at https://clinicaltrials.gov/ct2/show/NCT01913353.

Tags: BioterrorismSelect AgentsSmallpoxUSAMRIIDVaccines

Related Posts

Medical Countermeasure Development
Funding News

2021 BAA for Development of Medical Countermeasures for Biological Threats

March 2, 2021
How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?
Medical Countermeasures

How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?

March 2, 2021
Key Questions About South Africa’s Vaccine Rollout Plan
Medical Countermeasures

Key Questions About South Africa’s Vaccine Rollout Plan

March 2, 2021
Can Vaccinated People Still Spread the Coronavirus?
Public Health

Can Vaccinated People Still Spread the Coronavirus?

February 26, 2021
Load More

Latest News

Medical Countermeasure Development

2021 BAA for Development of Medical Countermeasures for Biological Threats

March 2, 2021
UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)

UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)

March 2, 2021
New Coronavirus Variant: Here Is What Scientists Know About B1525

New Coronavirus Variant: Here Is What Scientists Know About B1525

March 2, 2021
How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?

How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?

March 2, 2021

Subscribe

Upcoming Events

Mar 8
Virtual Event
March 6 - March 10

CROI 2021 – Conference on Retroviruses and Opportunistic Infections

Mar 8
Virtual Event
March 8 - March 10

Quantum-Enabled Sensing and Imaging for Biology

Mar 8
Virtual Event
2:00 pm - 3:30 pm

TRB Webinar: Visualizing Effects of COVID-19 on Transportation: A One-Year Retrospective

Mar 9
Virtual Event
March 9 - March 11

The Current Global Governance Landscape for Influenza

Mar 9
Virtual Event
March 9 @ 11:00 am - March 10 @ 4:00 pm EST

Rapid Response by Laboratory Animal Research Institutions During the COVID-19 Pandemic

View More
  • About
  • Contact
  • Privacy
  • Subscribe

© 2021 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe

© 2021 Stemar Media Group LLC